Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts.

6 patients with refractory anaemia with excess blasts (RAEB) were treated with a new oral anthracycline, idarubicin. 3 patients achieved complete remission, and the remaining 3 achieved partial remission. These responses were maintained for 8-60 wk, the longer durations being in the patients who achieved complete remission. Treatment was given on an outpatient basis, and all but 1 patient remained at home for most of the disease course. Unwanted effects were mild. It would thus appear that oral idarubicin is an effective treatment for RAEB, in addition to allowing outpatient management. Larger studies are required for further evaluation.
AuthorsE Johnson, L A Parapia
JournalEuropean journal of haematology (Eur J Haematol) Vol. 39 Issue 3 Pg. 278-81 (Sep 1987) ISSN: 0902-4441 [Print] DENMARK
PMID3479336 (Publication Type: Journal Article)
Chemical References
  • Idarubicin
  • Daunorubicin
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anemia, Refractory, with Excess of Blasts (drug therapy)
  • Daunorubicin (adverse effects, analogs & derivatives, therapeutic use)
  • Humans
  • Idarubicin
  • Recurrence
  • Remission Induction
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: